for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beyondspring Inc

BYSI.OQ

Latest Trade

12.37USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

11.26

 - 

25.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.37
Open
--
Volume
--
3M AVG Volume
1.13
Today's High
--
Today's Low
--
52 Week High
25.79
52 Week Low
11.26
Shares Out (MIL)
27.82
Market Cap (MIL)
356.60
Forward P/E
-10.34
Dividend (Yield %)
--

Latest Developments

More

Beyondspring Announces Proposed Public Offering Of Ordinary Shares

Beyondspring Enrolls First Patient In Global Phase 3 Clinical Trial To Prevent Chemotherapy-Induced Neutropenia

Beyondspring Inc Qtrly Net Loss Per Share $0.32

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beyondspring Inc

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.

Industry

Biotechnology & Drugs

Contact Info

28 Liberty St Fl 39

+1.646.5284184

https://www.beyondspringpharma.com/en/

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-4.400

2018

-2.420

2019(E)

-1.240
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-1,045.47
Return on Equity (TTM)
-292.33

Latest News

Latest News

BRIEF-BeyondSpring Says Richard Brand Resigned As CFO

* BEYONDSPRING SAYS RICHARD A. BRAND RESIGNED AS CHIEF FINANCIAL OFFICER OF CO EFFECTIVE AS OF FEBRUARY 20, 2018 - SEC FILING

BRIEF-BeyondSpring Appoints Patrick Fabbio To Board As An Independent Member

* BEYONDSPRING APPOINTS LIFE SCIENCES VETERAN PATRICK FABBIO TO BOARD OF DIRECTORS AS AN INDEPENDENT MEMBER Source text for Eikon: Further company coverage:

BRIEF-BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin

* BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN)

BRIEF-Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China

* BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY

BRIEF-BeyondSpring qtrly loss per share $‍0.68

* BeyondSpring reports third quarter 2017 operational and financial results

BRIEF-BeyondSpring announces first patient enrolled in China

* BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia

BRIEF-China FDA approves ctas for Beyondspring's second global plinabulin registrational trial

* China FDA approves ctas for beyondspring’s second global plinabulin registrational trial for chemotherapy-induced neutropenia prevention

BRIEF-BeyondSpring Q1 loss per share $2.66

* Beyondspring inc qtrly basic and diluted loss per share of $2.66

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up